



September 29, 2025

# PRESS RELEASE

## IFIGENEIA project CY-Hub Infoday Meeting

On 29<sup>th</sup> September, 2025, the first meeting of the Cyprus Hub of the European Project IFIGENEIA was held, in Nicosia, with the aim of communicating the Project to relevant stakeholders.

The event brought together representatives from the Ministry of Health, the Academic Community, PASYKAF, OKYPY, the University of Cyprus, the German Oncology Center and the Bank of Cyprus Oncology Center. Also present was the Project Coordinator and the coordination team from the Aristotle University of Thessaloniki. The presentation of the Project provided all attendees the opportunity to exchange views, knowledge, and connect as well as explore new collaborations.

The IFIGENEIA Project will last four years, and it is funded by the European Union with €6 million. The Project aims to strengthen innovation, sustainability and transnational cooperation at a European level. IFIGENEIA concerns the development of specifications for a center for the production of radioisotopes and radiopharmaceuticals mainly for cancer with the aim of securing funding for its creation.

The project involves 22 partners from 6 countries in 4 hubs of excellence involving Greece, Slovenia and Cyprus and the training hub in Bosnia and Herzegovina. The Cyprus hub consists of RTD TALOS, OKYPY, the University of Cyprus and PASYKAF.

**IFIGENEIA**  
Innovative Facility for Isotope GENERation with Efficient Ion Accelerator

**Project Details**  
Starting Date: 01/03/2025 | Total Budget: € 6,000,000  
End Date: 28/02/2029 | 22 Partners from 6 countries

**Project Objectives**

- Develop a comprehensive design and business plan for a LINAC-based facility
- Establish regional Excellence Hubs in Greece, Slovenia and Cyprus as well as foster interregional cooperation in nuclear medicine and related sectors
- Seek new public and private funding to establish the facility beyond the project
- Enable sustainable, tunable production of medical radioisotopes
- Mentor and prepare future hubs in Western Balkan countries

**Project Consortium**

Logos of consortium members: dkfz, Aristotle University of Thessaloniki, University of Cyprus, Jacob Stefan Institute, Ljubljana, Slovenia, REGION OF CENTRAL MACEDONIA, TECHNOPOLIS, PASYKAF, ARCHAEOLOGICAL MUSEUM OF THESSALONIKI, OKYPY, GSI, SLOVENIAN ACADEMY OF ENGINEERING, BIKOSMOS, COSYLAB, IMF, YFOS.



CY-Hub Info day / Meeting



## More information

- Aristotle University of Thessaloniki, Greece,  
Prof Dimitrios Sampsonidis, IFIGENEIA Project Coordinator
- Jožef Stefan Institute, Slovenia,  
Ms Urska Mrgole, urska.mrgole(at)ijs.si, IFIGENEIA Communication and Dissemination Manager

## About project

The **IFIGENEIA Project** aspires to introduce, develop and deliver the complete design study and the precise business plan for the implementation of the LINear ACcelerator (LINAC) technology in radiation therapy, diagnostic and theragnostic (a treatment that combines therapeutics with diagnostics) procedures in Europe. The objective of the IFIGENEIA project is to create the complete design and implementation study for a cutting-edge LINAC facility in the Balkans. This will be achieved by establishing Excellence Hubs in Greece, Slovenia, and Cyprus. These hubs will be dedicated to developing and implementing a LINAC-based facility capable of producing a diverse range of marketable radioisotopes for medical, industrial, and research applications. LINAC technologies offer a unique, compact, cost-effective, and environmentally friendly solution for sustainable production, management, accessibility, and promotion of nuclear medicine and molecular imaging technologies. Unlike current radioisotope production methods, mostly reliant on older nuclear reactors using highly enriched uranium with associated concerns about global availability, safety, and environmental issues, or on cyclotrons limited to a narrow range of radioisotopes, LINACs enable the production of a broader range due to their tunability in energy, targets, and currents.

## Partners



Funded by  
the European Union

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. Grant Agreement No: 101186921.



in